AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.300

-0.050-2.13%

Volume:1.98M

Turnover:4.60M

Market Cap:2.97B

PE:-19.12

High:2.360

Open:2.350

Low:2.300

Close:2.350

52wk High:3.310

52wk Low:1.515

Shares:1.29B

Float Shares:786.49M

Volume Ratio:1.00

T/O Rate:0.25%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.120

EPS(LYR):-0.120

ROE:-18.95%

ROA:-5.37%

PB:3.49

PE(LYR):-19.12

Loading ...

Overview Company News Filings

Mesoblast Limited to Host Half-Year Financial Results Webcast

Mesoblast (ASX:MSB) Valuation In Focus As Ryoncil Data And New Trial Plan Signal Clinical Momentum

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use

Simply Wall St.

Mesoblast Reports High Survival With Ryoncil in SR-aGvHD and Plans Adult Pivotal Trial

Stock Track | Mesoblast Soars 6.73% Intraday as JPMorgan Chase Becomes Substantial Holder

Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%

MT Newswires Live

Stock Track | Mesoblast Plummets 5.02% Intraday Amid Ryoncil Expansion Plans and Financial Concerns

ASX Growth Companies With High Insider Stakes To Watch

Simply Wall St.

Mesoblast (ASX:MSB) Is Down 7.4% After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial – Has The Bull Case Changed?

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 8.0% After Ryoncil’s Early Adoption And Adult Expansion Push - Has The Bull Case Changed?

Simply Wall St.

Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%

MT Newswires Live

Mesoblast Reports US$30 Million Net Revenue for Second Fiscal Quarter 2026

Ryoncil® Net Revenues Increase for the Quarter to US$30M

THOMSON REUTERS

Mesoblast (ASX:MSB) Valuation Check As Ryoncil Access And Early Commercial Outcomes Progress

Simply Wall St.

Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities

Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities

Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting

MT Newswires Live

BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd

Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd

THOMSON REUTERS

Mesoblast Reports 84% Survival in Children Using Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.3,"timestamp":1771909920000,"preClose":2.35,"halted":0,"volume":1980179,"delay":0,"changeRate":-0.021276595744680965,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.12031418214088135,"marketStatus":"Not Yet Opened","change":-0.05,"latestTime":"02-24 16:12:00 AEDT","open":2.35,"high":2.36,"low":2.3,"amount":4595910,"amplitude":0.025532,"askPrice":2.31,"askSize":300,"bidPrice":2.3,"bidSize":2184,"shortable":3,"etf":0,"ttmEps":-0.12031418214088135,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771974000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.35,"openAndCloseTimeList":[[1771887600000,1771909200000]],"volumeRatio":1.001047,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-5.37%","roe":"-18.95%","lyrEps":-0.12027,"volumeRatio":1.001047,"shares":1290302187,"dividePrice":0,"high":2.36,"amplitude":0.025532,"preClose":2.35,"low":2.3,"week52Low":1.515,"pbRate":"3.49","psRate":"121.34","week52High":3.31,"institutionHeld":0,"latestPrice":2.3,"committee":0.758454,"eps":-0.12031418214088135,"divideRate":0,"volume":1980179,"delay":0,"ttmEps":-0.12031418214088135,"open":2.35,"prevYearClose":2.72,"prevWeekClose":2.41,"prevMonthClose":2.53,"prevQuarterClose":2.72,"fiveDayClose":2.41,"twentyDayClose":2.69,"sixtyDayClose":2.72,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612340261","title":"Mesoblast Limited to Host Half-Year Financial Results Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2612340261","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612340261?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:00","pubTimestamp":1771588846,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5qVvJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","SG9999014013.SGD","BK7501","BK7067","BK7508","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","MSB.AU","LU2095319765.USD","BK4585","SG9999014005.SGD","SG9999014039.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","SG9999014021.USD","NDAQ"],"gpt_icon":0},{"id":"2612286639","title":"Mesoblast (ASX:MSB) Valuation In Focus As Ryoncil Data And New Trial Plan Signal Clinical Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2612286639","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612286639?lang=en_us&edition=fundamental","pubTime":"2026-02-19 19:21","pubTimestamp":1771500069,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has presented new clinical data for Ryoncil to transplant specialists, reporting consistently high survival outcomes in steroid refractory acute graft versus host disease across multiple patient groups.\nSee our latest analysis for Mesoblast.\nThe latest Ryoncil data arrives after a mixed price run, with Mesoblast’s 90 day share price return of 4.76% contrasting with a 12.64% decline year to date and a three year total shareholder return of 164.49%. This suggests long term...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-as-ryoncil-data-and-new","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-in-focus-as-ryoncil-data-and-new","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","MSB","BK7501","BK7508","MSB.AU","BK4006"],"gpt_icon":0},{"id":"2611151472","title":"Mesoblast (ASX:MSB) Is Up 6.7% After Adult Ryoncil Data Readout Validates Earlier Second-Line Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2611151472","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611151472?lang=en_us&edition=fundamental","pubTime":"2026-02-13 16:38","pubTimestamp":1770971928,"startTime":"0","endTime":"0","summary":"In February 2026, Mesoblast reported data from patients treated under the U.S. Emergency Investigational New Drug program showing that its FDA-approved cell therapy Ryoncil® (remestemcel-L-rknd) achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease across children and adults, at different treatment lines and regardless of ruxolitinib use or resistance.\nThe findings, which highlighted better completion of treatment and survival when Ryoncil was used...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-67-after-adult-ryoncil-data-readout-v","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-67-after-adult-ryoncil-data-readout-v","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","BK7501","MSB.AU","MSB","BK4006"],"gpt_icon":0},{"id":"2610603319","title":"Mesoblast Reports High Survival With Ryoncil in SR-aGvHD and Plans Adult Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2610603319","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610603319?lang=en_us&edition=fundamental","pubTime":"2026-02-12 07:28","pubTimestamp":1770852483,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has announced new data presented at the February 2026 meetings of the American Society for Transplantation and Cellular Therapy  and the Center for Blood and Marrow Transplant Research . The results showed that Ryoncil  achieved similarly high survival outcomes in steroid-refractory acute graft-versus-host disease  when used in both children and adults, regardless of whether it was used as a second or third line treatment, and in patients who were either naive or resistant to ruxolitinib. Ryoncil is currently the only FDA-approved mesenchymal stromal cell product for any indication and is approved for children under age 12 with SR-aGvHD. Mesoblast plans to initiate a pivotal trial to evaluate early use of Ryoncil as a second-line treatment in adults with severe SR-aGvHD, following protocol approval by the central Institutional Review Board. If successful, this trial may support label extension for adult use. The presented results highlight the importance of early trea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL41Dxt1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014021.USD","BK7067","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","BK4112","BK4585","BK7501","LU2210150020.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014039.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","MSB.AU","BK7508","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"1101862323","title":"Stock Track | Mesoblast Soars 6.73% Intraday as JPMorgan Chase Becomes Substantial Holder","url":"https://stock-news.laohu8.com/highlight/detail?id=1101862323","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101862323?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:26","pubTimestamp":1770607581,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 6.73% during Monday's intraday trading session, following a significant corporate development.The sharp rise comes after the company disclosed that JPMorgan Chase & Co....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"2610507905","title":"Mesoblast Says JPMorgan Chase Becomes Substantial Holder; Shares Rise 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610507905","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610507905?lang=en_us&edition=fundamental","pubTime":"2026-02-09 11:23","pubTimestamp":1770607397,"startTime":"0","endTime":"0","summary":"Mesoblast  received notice that JPMorgan Chase and its affiliates became a substantial holder of the company on Feb. 4, according to a Monday filing with the Australian bourse.JPMorgan Chase now owns 65.2 million shares in the company, representing 5.05% voting power, the filing said.Shares of the company rose 6% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2552382215.SGD","LU0208291251.USD","LU2023250504.SGD","LU2357305700.SGD","LU2505996509.AUD","LU1064131342.USD","IE00BN8TJ469.HKD","LU2430703251.USD","LU1914381329.SGD","LU0256863811.USD","LU0417517546.SGD","LU2462157665.USD","LU0820562030.AUD","IE00BKVL7J92.USD","BK4533","LU2054465674.USD","LU2264538146.SGD","LU1280957306.USD","LU2430703178.SGD","IE00BJTD4N35.SGD","LU0942090050.USD","BK4534","LU0238689110.USD","IE00BFXG1179.USD","BK4516","LU1366192091.USD","LU2023250843.SGD","MESO","BK4207","IE0034235303.USD","LU0787776722.HKD","LU0971096721.USD","IE00B1BXHZ80.USD","LU1551013342.USD","LU1244550577.SGD","LU1894683264.USD","LU0640476718.USD","JPM","LU0320765489.SGD","LU2592432038.USD","BK4550","IE00BDCRKT87.USD","LU1894683348.USD","LU1116320737.USD","BK4504","IE00BYXW3230.USD","LU0149725797.USD","MSB.AU","LU1032466523.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"1182252637","title":"Stock Track | Mesoblast Plummets 5.02% Intraday Amid Ryoncil Expansion Plans and Financial Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1182252637","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182252637?lang=en_us&edition=fundamental","pubTime":"2026-02-06 07:03","pubTimestamp":1770332603,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock plummeted 5.02% during intraday trading on Friday, reflecting significant selling pressure.The price movement follows the company's announcement regarding the expansion of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"gpt_icon":0},{"id":"2609538068","title":"ASX Growth Companies With High Insider Stakes To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2609538068","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609538068?lang=en_us&edition=fundamental","pubTime":"2026-02-06 03:08","pubTimestamp":1770318490,"startTime":"0","endTime":"0","summary":"As the Australian market faces a slightly lower opening amid global tech sector challenges, investors are increasingly cautious, influenced by Wall Street's recent downturn and upcoming central bank meetings. In this climate, growth companies with high insider ownership can be particularly appealing as they often signal strong internal confidence and alignment with shareholder interests.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2053000-choice1-main-header/1585186555515"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-emr/emerald-resources-shares/news/asx-growth-companies-with-high-insider-stakes-to-watch","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-emr/emerald-resources-shares/news/asx-growth-companies-with-high-insider-stakes-to-watch","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7093","NWF.AU","EMR.AU","LM8.AU","BK7117","BK7501","MSB.AU","AV1.AU","SEA.AU","TTT.AU","BK7116","BK7036","BK7084","BK7067","BK7508","CAT.AU","BK7016","BK7104","BK7095","BK7017","3DP.AU","EIQ.AU","WZR.AU","ELS.AU","AEM.AU","BK7506"],"gpt_icon":0},{"id":"2609301714","title":"Mesoblast (ASX:MSB) Is Down 7.4% After Expanding Ryoncil Access And Planning Adult SR-aGvHD Trial – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301714","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609301714?lang=en_us&edition=fundamental","pubTime":"2026-02-05 19:25","pubTimestamp":1770290755,"startTime":"0","endTime":"0","summary":"Mesoblast Limited reported past real-world use of Ryoncil (remestemcel-L-rknd) in pediatric steroid-refractory acute graft-versus-host disease, alongside expanding U.S. transplant center onboarding and broad government and commercial reimbursement coverage via a dedicated MyMesoblast access hub and a specific CMS J-Code.\nThe company also plans to widen Ryoncil’s label into the much larger adult SR-aGvHD population through a pivotal trial with the NIH-funded Bone Marrow Transplant Clinical...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-down-74-after-expanding-ryoncil-access-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-down-74-after-expanding-ryoncil-access-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MSB","MSB.AU","BK4197","BK7501","BK7067","BK4006","SR"],"gpt_icon":0},{"id":"2607001897","title":"Mesoblast (ASX:MSB) Is Up 8.0% After Ryoncil’s Early Adoption And Adult Expansion Push - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607001897","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607001897?lang=en_us&edition=fundamental","pubTime":"2026-01-29 14:30","pubTimestamp":1769668251,"startTime":"0","endTime":"0","summary":"Mesoblast recently reported encouraging real-world use of its FDA-approved cell therapy Ryoncil for children with steroid-refractory acute graft-versus-host disease, alongside significant progress in payer coverage and transplant center onboarding since its 2025 launch.\nThe company is also moving to broaden Ryoncil’s use into the larger adult SR-aGvHD population, while advancing rexlemestrocel-L for chronic low back pain as a potential non-opioid option, underscoring how its cell therapy...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-80-after-ryoncils-early-adoption-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-80-after-ryoncils-early-adoption-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7067","BK4006","MSB","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2607776301","title":"Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607776301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607776301?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:13","pubTimestamp":1769656406,"startTime":"0","endTime":"0","summary":"Mesoblast  said a pivotal trial is expected to start site enrollment this quarter for the label extension of Ryoncil for use in adults with steroid-refractory acute graft-versus-host disease , according to a Thursday filing with the Australian bourse.Ryoncil is the company's mesenchymal stromal cell  therapy  for the treatment of patients aged 2 months and older, including adolescents and teenagers, with SR-aGvHD.Shares of the company fell nearly 4% in recent Thursday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK4575","MSB.AU","MESO","BK7067","MSC","BK7508","BK4150","BK4139"],"gpt_icon":0},{"id":"2607721092","title":"Mesoblast Reports US$30 Million Net Revenue for Second Fiscal Quarter 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2607721092","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607721092?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:54","pubTimestamp":1769644471,"startTime":"0","endTime":"0","summary":"Mesoblast Limited reported net revenues of US$30 million for the second fiscal quarter ended December 31, 2025, driven by Ryoncil sales, which saw gross sales of US$35 million—a 60% increase compared to the previous quarter. The company also announced the establishment of a new non-dilutive credit line totaling US$125 million at a fixed interest rate of 8.00% per annum, replacing existing debt facilities and featuring a five-year interest-only period. As of December 31, 2025, Mesoblast held US$130 million in cash, with a net operating cash spend of US$16 million for the quarter. The company expects reduced net cash spend for the remainder of the fiscal period due to projected revenue and expense controls. Operational highlights included progress in the confirmatory Phase 3 trial MSB-DR004 for rexlemestrocel-L and positive FDA feedback regarding a potential Biologics License Application filing for rexlemestrocel-L in chronic discogenic low back pain patients.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL6SgrR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","BK7067","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4112","LU0314104364.USD","BK7508","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","MSB.AU","LU2095319765.USD","BK4588","BK7501","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2607721096","title":"Ryoncil® Net Revenues Increase for the Quarter to US$30M","url":"https://stock-news.laohu8.com/highlight/detail?id=2607721096","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607721096?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:54","pubTimestamp":1769644449,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nTUABPSVTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","MSB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2606699577","title":"Mesoblast (ASX:MSB) Valuation Check As Ryoncil Access And Early Commercial Outcomes Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2606699577","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606699577?lang=en_us&edition=fundamental","pubTime":"2026-01-28 09:35","pubTimestamp":1769564151,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after reporting early commercial experience with Ryoncil in children with steroid refractory acute graft versus host disease, along with broader US access and reimbursement progress.\nSee our latest analysis for Mesoblast.\nThat clinical and reimbursement progress comes after a mixed year for the stock, with a 7.17% 90 day share price return, a 7.24% 30 day share price decline, and a very large 3 year total shareholder return of 198.64%. This suggests longer...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-ryoncil-access-and-early","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-ryoncil-access-and-early","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK4097","LU2065732104.USD","MSB.AU","PRGS","BK7508","BK4006","BK7067","MSB"],"gpt_icon":0},{"id":"2606786784","title":"Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786784","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786784?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"The integration strengthens Saber's payment solutions across remittances, payroll, and fintech sectors.SAN FRANCISCO, Jan. 27, 2026 /PRNewswire/ -- Saber, a leading cross-border payment infrastructure powered by Mudrex Inc., announced its integration with Circle Payments Network  as a Beneficiary Financial Institution . This strategic collaboration will enable Saber to offer instant fiat off-ramping services to businesses across the globe, leveraging stablecoins to facilitate seamless cross-border payments.\"Our Integration with Circle Payment Network is a significant milestone in our mission to make global money movement seamless and accessible,\" said Edul Patel, CEO and Co-founder of Mudrex and Saber. \"Through this collaboration, we aim to improve payment solutions and help businesses worldwide join the digital economy.\" We strongly believe stablecoins are fundamentally changing how money moves across borders, and CPN is an important step in this transformation.\". Saber's integration ","market":"nz","thumbnail":"https://mma.prnewswire.com/media/2870402/Saber_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2870402/Saber_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/saber-integrates-with-circle-payments-network-to-strengthen-global-off-ramp-capabilities-302671122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4145","IE00B19Z4B17.USD","BK7506","BK4209","BK4006","MSB.AU","BK7501","IE0031619046.USD","CPN.AU","BK7067","BK7508","MSB","BFI","IE00B66KJ199.SGD","IE00B7SZL793.SGD","CPN","BK7095","CTS"],"gpt_icon":0},{"id":"2606778420","title":"Saber Integrates with Circle Payments Network to Strengthen Global Off-Ramp Capabilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2606778420","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606778420?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"The integration strengthens Saber's payment solutions across remittances, payroll, and fintech sectors.SAN FRANCISCO, Jan. 27, 2026 /CNW/ -- Saber, a leading cross-border payment infrastructure powered by Mudrex Inc., announced its integration with Circle Payments Network  as a Beneficiary Financial Institution . This strategic collaboration will enable Saber to offer instant fiat off-ramping services to businesses across the globe, leveraging stablecoins to facilitate seamless cross-border payments.\"Our Integration with Circle Payment Network is a significant milestone in our mission to make global money movement seamless and accessible,\" said Edul Patel, CEO and Co-founder of Mudrex and Saber. \"Through this collaboration, we aim to improve payment solutions and help businesses worldwide join the digital economy.\" We strongly believe stablecoins are fundamentally changing how money moves across borders, and CPN is an important step in this transformation.\". Saber's integration with CP","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2870402/Saber_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2870402/Saber_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/saber-integrates-with-circle-payments-network-to-strengthen-global-off-ramp-capabilities-801219019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPN","BK4145","BK7506","BK7508","BK4209","BK7501","IE00B66KJ199.SGD","MSB","BFI","IE0031619046.USD","IE00B19Z4B17.USD","CPN.AU","IE00B7SZL793.SGD","BK7067","CTS","BK7095","BK4006","MSB.AU"],"gpt_icon":0},{"id":"2606276103","title":"Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting","url":"https://stock-news.laohu8.com/highlight/detail?id=2606276103","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606276103?lang=en_us&edition=fundamental","pubTime":"2026-01-27 10:38","pubTimestamp":1769481531,"startTime":"0","endTime":"0","summary":"Mesoblast  said 21 of the first 25, or 84%, patients treated with its Ryoncil product in a \"real-world\" clinical setting post-launch were alive and completed the initial 28-day treatment regimen as per the US Food and Drug Administration  approval label, according to a Tuesday Australian bourse filing.The four remaining patients had been offered and failed other therapies before the use of Ryoncil and died of severe steroid-refractory acute graft-versus-host disease within 28 days, per the filing.The firm established a patient access hub termed MyMesoblast to allow patients to order Ryoncil. It has onboarded 45 transplant centers, and it is targeting the onboarding of 64 centers.Its shares fell nearly 1% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7501","MSB.AU","BK7508","BK4139","MESO"],"gpt_icon":0},{"id":"2606622245","title":"BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2606622245","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606622245?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:48","pubTimestamp":1769471314,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-AgvhdJan 26 (Reuters) - Mesoblast Ltd MSB.AX:MESOBLAST LTD - RYONCIL SHOWS 84% SURVIVAL RATE IN CHILDREN WITH SR-AGVHDSource text: ID:nGNX7tzB2cFurther company coverage: MSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MESO","BK7501","BK7067","MSB.AU","BK7508","BK4139"],"gpt_icon":0},{"id":"2606922243","title":"Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2606922243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606922243?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:47","pubTimestamp":1769471227,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nFWN3YR0QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7067","BK7501","BK7508","MSB.AU","MESO"],"gpt_icon":0},{"id":"2606107222","title":"Mesoblast Reports 84% Survival in Children Using Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2606107222","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606107222?lang=en_us&edition=fundamental","pubTime":"2026-01-27 07:45","pubTimestamp":1769471154,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has announced an update on the commercial experience with Ryoncil , the first mesenchymal stromal cell  product approved by the U.S. Food & Drug Administration  for any indication. Since its commercial availability in March 2025 for children aged 2 months and older with steroid-refractory acute graft-versus-host disease , real-world data from the first 25 patients treated showed an 84% survival rate after completing the initial 28-day treatment regimen. Mesoblast is also preparing to expand the FDA label for Ryoncil to adults with severe SR-aGvHD, with a pivotal trial in adults to be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network  expected to commence site enrollment this quarter. The company has established the MyMesoblast patient access hub and coverage for Ryoncil now extends to more than 260 million U.S. lives through government and commercial payers. Results from the adult pivotal trial are yet to be presented.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDLMhWV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210149790.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","MSB.AU","SG9999014005.SGD","SG9999014021.USD","NDAQ","BK7508","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK7501","SG9999014039.USD","IE00BGHQF748.EUR","BK7067","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4112"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":135,"code":"91000000","status":"200"}]}}